Kornimate/medical-research-clean huggingface dataset:
validation of a screening tool for swallowing disorders for the elderly

Conditions: Swallowing Disorder; Dysphagia

Summary: swallowing disorder, or dysphagia, is a lack of protection of the airways during the passage of the food bolus towards the esophagus. swallowing disorder is characterized by a feeling of discomfort when swallowing, difficult swallowing in elderly people or a blockage felt during the progression of food between the mouth and the stomach, sometimes with falsities. these disorders can be the cause of a loss of appetite and a reduction in food consumption in older people. in the most serious cases, they can lead to aspiration, weakening the pulmonary passages and possibly leading to suffocation. swallowing disorders constitute an important public health problem due to their prevalence among the elderly. many early readmissions could be avoided thanks to better quality of care in these patients. in the elderly, the number of comorbidities and the multiplicity of medications and drug intake increase the incidence of swallowing disorders in this population. they constitute a common pathology, probably underestimated and underdiagnosed in the geriatric population. given the aging of the martinique population, it is appropriate to offer an easy-to-use, quickly achievable tool for diagnostic purposes, making it possible to quickly identify potential swallowing disorders, and therefore to anticipate meal intake, and on the adaptation of the prescription to a medicinal alternative (before any food or medication taken during hospitalization). in the geriatric short-stay unit of the martinique university hospital, a tool called "deglut'g", was developed, and has been used since 2015, in order to allow caregivers a rapid, reliable and relevant assessment of swallowing disorders in the elderly, in order to guide care and medication alternatives.it now appears important to validate this tool, by comparing it with the results of examinations of swallowing disorders obtained from a speech-language pathologists (slps) and an ent doctor.


Eligibility criteria:
inclusion criteria: * person aged 75 or over hospitalized in the geriatric short-stay unit, * person having been informed of the research, * person having given free written and informed consent, * person affiliated to a social security scheme. exclusion criteria: * person unable to take the tests, * person with an oral condition that hinders normal swallowing (stomatitis, gingivitis, etc.), * elderly person under legal protection, under guardianship or curatorship, * person who refused to participate in the study.

Keywords: swallowing disorder dysphagia swallowing disorder test bronchopneumonia geriatric short-stay unit
68ga-dotatoc pet for the evaluation of gastroenteropancreatic neuroendocrine tumours

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

Summary: gastroenteropancreatic neuroendocrine tumours (gep-nets) are a heterogeneous group of neoplasms that arise from the endocrine cells of the gastroenteropancreatic tract. the diagnostic work-up of these tumours include computed tomography (ct), endoscopic ultrasound (eus), magnetic resonance imaging (mri). the majority of these tumours express somatostatin receptors on their surface. for this reason, in addition to traditional imaging exams, diagnostic work-up of gep-nets should include a positron emission tomography/ct with 68ga labeled somatostatin analogues targeting somatostatin receptors with high sensitivity and specificity. 68ga-dotatoc pet/ct scan is a corner stone to assess gep- net patients at different stage of disease and it is the standard functional imaging modality to study well-differentiated pan-nets, as reported in the being also included in the guidelines of the european association of nuclear medicine (eanm). moreover, quantitative parameters extracted from 68ga- dota-peptides pet imaging have demonstrated their prognostic utility as markers for progression-free survival and disease specific mortality in patients affected by net. additionally, 18f-fdg pet can be used for evaluating the possible presence ofa high-grade component within the tumour itself. the accurate morphofunctional characterization is of utmost importance in the field of gep-net. the advent of new hybrid scanners, namely pet/mri, opens the way to an innovative diagnostic work- up that can be applied to gep-nets. in fact, mri plays a role as morphological imaging modalities for a better characterization of soft-tissue and liver parenchyma compared to ct; moreover, the low radiation exposure related to mri, makes this imaging modality more suitable for patients requiring several imaging during follow-up. patients requiring 68ga-dota peptides (68ga-dotatoc) pet scan and eventually mri scan, can be studied in a single session examination, by using 68ga-dotatoc pet/mri. considering the rarity of gep_nets, it is quite difficult to collect a sufficient number of patients in order to investigate the accuracy, predictive and prognostic value of the currently available imaging technique in this scenario. based on these considerations, the possibility to analyze pet images deriving from both pet/ct and pet/mri scans of patients affected by gep-net is of fundamental relevance in order to provide answers to the currently unmet clinical needs.


Eligibility criteria:
inclusion criteria: * patients with either histological diagnosis of gep-net at radiologic imaging and referred to 68ga-dotatoc pet; * age \> 18 years old; * willing to provide a signed informed consent. exclusion criteria: * controindications to mr study (i.e. pacemaker); * age\< 18 years old.
injectable platelet rich fibrin in periodontal treatment

Conditions: Periodontitis

Summary: the aim of this randomized controlled parallel clinical trial is to investigate the efficacy of injectable platelet rich fibrin (iprf) as an adjunctive to non-surgical periodontal therapy (step 1 \& 2 of periodontal treatment). thirty-two (32) patients diagnosed with stage iii periodontitis will be randomly assigned to two study groups. participants will receive non-surgical periodontal treatment only (control group) or non-surgical periodontal treatment with iprf (test group). patients will receive step 1 and 2 of periodontal treatment. step 2 of periodontal treatment will be completed in one visit. test group also will receive immediately after the subgingival instrumentation iprf at the sites with ppd≥5mm. subgingival plaque will be collected with paper points at different time points- baseline: before treatment, 3 and 6 months after treatment. the presence and quantification of bacteria: -porphyromonas gingivalis (pg), filifactor alocis (f.alocis)- will be examined with quantitative polymerase chain reaction (q pcr). clinical parameters, including bleeding on probing (bop), probing pocket depth (ppd), clinical attachment level (cal), gingival recession (rec) will be recorded at baseline, 3 and 6 months after treatment. patient satisfaction will be assessed through questionnaires regarding quality of life, pain perception and the use of analgesics. the questionnaires will be completed one week after subgingival instrumentation.


Eligibility criteria:
inclusion criteria: * ages eligible for study: \>18 years old (adults) * diagnosed periodontitis stage iii * presence of ≥ 15 teeth * signed written consent form by patient exclusion criteria: * at least one edentulous jaw * need for chemoprophylaxis before treatment * periodontal treatment the last 6 months * antibiotic treatment the last 6 months * immunomodulatory diseases (e.g. diabetes mellitus, rheumatoid arthritis, osteoporosis), for which patients do not take medication * hba1c\> 7.0% in patients with diabetes * pregnancy/ lactation * medications or undergoing treatment which may affect mucosal healing

Keywords: periodontitis platelet rich fibrin non surgical porphyromonas gingivalis filifactor alocis pocket closure
pharmaco mechanical thrombolysis associated with anticoagulation compared with anticoagulation in the acute phase of very symptomatic proximal venous thrombosis of the lower limbs.

Conditions: Iliofemoral Venous Thrombosis

Summary: * iliofemoral dvts (if dvts) are vascular disorders associated with high morbidity and mortality, which can be complicated by long-term post-thrombotic syndrome (pts). * pharmaco mechanical thrombolysis (pmt) is an innovative endovascular technique involving in situ fibrinolysis of the thrombus in the acute phase of thrombosis, followed by mechanical extraction by fragmenting the thrombus. * the american attract study showed that management by catheter-directed thrombolysis and/or pmt in the acute phase is safe and effective at 2 years in a subgroup of dvtif compared with anticoagulation (18% moderate or severe spt with thrombolysis vs. 28% without thrombolysis). * pmt-dvt will be the first study to assess the medium (30 months) and long-term (60 months) efficacy of pmt in the french context, using data from the french national health data system.

patients with acute iliofemoral thrombosis will be included in the study after consent. they will be randomized to pharmaco-mechanical thrombolysis combined with anticoagulant therapy with direct oral anticoagulant versus direct anticoagulant therapy alone. they will be monitored, and patients in the anticoagulation-only group may undergo stenting angioplasty in the chronic phase if they present a moderate post-thrombotic syndrome or venous claudication. at the end of 30 months, a medico-economic analysis will be carried out.

Eligibility criteria:
inclusion criteria: * patients who agreed to participate in the study and gave oral consent. * patient affiliated to a social security scheme * iliac and/or common femoral venous thrombosis * recent thrombosis less than or equal to 14 days since qualifying imaging or less than or equal to 21 days since onset of symptoms and at least 1 of the following criteria: * visual analog scale greater than or equal to 5 and/or * venous claudication and/or * increase in thigh circumference greater than or equal to 5% compared with contralateral thigh. exclusion criteria: * patients with superficial femoral or popliteal venous thrombosis without involvement of the common femoral or iliac veins. * patients with isolated thrombosis of the inferior vena cava, without extension to the iliac veins. * thrombosis of inferior vena cava proximal to the renal veins. * minors, pregnant women, adults under guardianship. * chronic renal failure with creatinine clearance below 30ml/min according to cockroft. * ischaemic phlebitis: proximal venous thrombosis associated with limb ischemia and impaired arterial flow.
analgecine for the treatment of neuropathic pain

Conditions: Neuropathic Pain

Summary: a randomized, open-label , positive drug controlled (neurotropin,japan organs pharmaceutical co., ltd. ), multi-center study to evaluate analgecine's efficacy and safety for the treatment of neuropathic pain.

the study was designed to evaluate the efficacy and safety of analgecine for the treatment of neuropathic pain for 2 weeks. it was a randomized, open-label , positive drug controlled, multi-center study phase iii clinical trial. patients were recruited with age between 18 and 80 and visual analysis scale (vas) between 3 and 8. after randomization, subjects were divided into 2 groups: 1) treatment with analgecine as experiment group; 2) treatment with neurotropin as positive control group. there are 3 measurement time points on day 0, 7, 14 after treatment to score patients pain with vas. the changes of the vas score at day 14 were compared between groups.

Eligibility criteria:
inclusion criteria: 1. patients with the established medical records; 2. patients with age of 18 years to 80 years old. 3. patients with neuropathic pain 4. patients at child-bearing age with negative pregnancy tests and contraceptive measures ( oral or injectable contraceptives) taken throughout the course of the experiment 5. patients with signed informed consent. exclusion criteria: 1. patients younger than 18 years old or older 80 years old 2. patients of dementia who can not determine efficacy 3. patients who was pregnant, nursing or who may become pregnant in the study course and did not take effective contraceptive measures. 4. patients with the history of allergic reactions 5. patients suffering from tuberculosis, cancer and other organic disease 6. patients who are alcoholics and drug addicts 7. others who were determined by physician not to be a candidate for this clinical observation
assessment of antioxidant therapy on oxidative stress biomarkers in type 2 diabetic patients with neuropathy

Conditions: Peripheral Diabetic Neuropathy

Summary: type 2 dm subjects having numbness, tingling and paresthesia in hands and feet (neuropathy) will be recruited. screening of neuropathy will be done by michigan screening instrument. this will be followed by nerve conduction studies. specific blood parameters will also be checked. the subjects will then be divided into four treatment arms. three groups will receive single drug and the fourth one will receive all the three drugs. these will be given for four months. follow up will be done every month. at the end of four months, they will be assessed for any improvement in neuropathy by using michigan neuropathy instrument and nerve conduction studies. blood parameters will also be measured again.

type 2 dm subjects having numbness, tingling and paresthesia in hands and feet (neuropathy) will be recruited. they will be screened by michigan neuropathy scale. this is tool used for screening neuropathy. subjects having a score equal to or greater then 4 will be examined for further evaluation. this will be followed by nerve conduction studies for objective assessment of neuropathy. for inclusion criteria the test performed will be hba1c, cbc, esr, rfts and lfts. after screening the baseline levels of superoxide radical, super oxide dismutase, glutathione peroxidase and malonaldehyde will be measured. the subjects will be randomly divided into four treatment arms. group a will receive triple regime antioxidant therapy including resveratrol 1500 mg two times a day, alpha lipoic acid 600 mg two times a day and superoxide dismutase 250 mg once a day. group b will receive resveratrol 1500mg bd, group c will be on tab alpha lipoic acid 600 mg bd and group d will take superoxide dismutase once a day. the subjects will be kept blinded about the medication. they will be followed every month in which their quality of life will be assessed using nottingham health profile and neuropathy will be assessed by michigan neuropathy scale. at the end of four months blood tests will again be performed to check the levels of superoxide radical, superoxide dismutase, glutathione peroxidase and malonaldehyde. ncs will be done to see any improvement in neuropathy.

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus * age between 40-60 years exclusion criteria: * malignancy * vitamin b12 deficiency * history of drug or alcohol abuse * taking antioxidant treatment * history and baseline investigations for renal hepatic and haematological diseases * pregnant or lactating women.

Keywords: diabetic neuropathy resveratrol alpha lipoic acid superoxide dismutase
mechanisms of change in brief treatment for borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: the present two-arm randomized controlled study aims at testing the effects (i.e., symptom reduction) and the underlying mechanisms of change associated with a brief psychiatric treatment (10 sessions over 4 months), compared with treatment as usual. participants undergo assessments at four points (intake, 2 months, discharge and 12 month follow-up). in addition to symptom measures, all individuals undergo a two-step assessment for the potential mechanisms of change (i.e., emotion and socio-cognitive processing): a) behavioural and b) neurofunctional. we hypothesize that change in the mechanisms explains the treatment effects. the present study uses an innovative treatment of bpd and at the same time a sophisticated assessment procedure to demonstrate the critical role of psychobiological change in emotion and sociocognitive processing in brief treatments. it will help increase the effectiveness of initial treatment phase for bpd and help diminish the societal burden of disease related with bpd. this study is funded by the swiss national science foundation (snsf).


Eligibility criteria:
inclusion criteria: * borderline personality disorder * age between 18 and 35 exclusion criteria: * non-mastery in french * neurological disorders * schizophrenia (according to dsm-5)
a study of two different dose combinations of nivolumab in combination with ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma

Conditions: Melanoma

Summary: the purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * subject must have been diagnosed with stage iii or/and stage iv histologically confirmed melanoma \[per american joint committee on cancer (ajcc) staging system\] that is unresectable or metastatic * eastern cooperative oncology group (ecog) performance status of 0-1 * subject has not been treated by systemic anticancer therapy for unresectable or metastatic melanoma exclusion criteria: * subjects with active brain metastases or leptomeningeal metastases * subjects with ocular melanoma * subjects with active, known or suspected autoimmune disease other protocol defined inclusion/exclusion criteria could apply
potassium-magnesium citrate as a blood pressure lowering agent in hypertensive patients

Conditions: Pre-hypertension; Hypertension

Summary: the goal of this study is to compare the effects of potassium magnesium citrate to potassium chloride on blood pressure among patients with pre-hypertension or mild hypertension. we will also test whether potassium magnesium citrate increases excretion of large amounts of sodium in the urine.


Eligibility criteria:
inclusion criteria: * age greater than 21 years * bmi \> 18.5 kg/m2 and \< 40 kg/m2 * prehypertension and mild hypertension: bp systolic 120-159 mmhg, diastolic 80-95 mmhg * must agree to limit lifestyle changes including: 1) embarking on a new exercise or weight reduction program 2) altering alcohol intake during the trial. exclusion criteria: * taking blood pressure lowering medication * diabetes mellitus * renal disease * active cardiac disease * active liver disease * chronic diarrhea * chronic nsaid use * active or suspected drug use * uncontrolled psychiatric disease * hiv infection * missed more than 20% of clinic visits in the last yr * prescription of diuretics for any reason * a patient taking nutritional supplements including multivitamins that is unwilling to discontinue them,\\ * consumption of greater than 14 alcoholic beverages per week

Keywords: pre-hypertension hypertension
iloperidone for symptoms of arousal in post traumatic stress disorder (ptsd)

Conditions: Post Traumatic Stress Disorder

Summary: a double-blind placebo-controlled random order crossover pilot study of iloperidone for symptoms of arousal in ptsd.

during period a, subjects will receive 8 weeks of iloperidone or placebo (2 weeks titration period followed by 6 weeks on stable dose). then they will be reassessed for response during period a; study drug will be discontinued and washed out over the following 2 weeks. they will then begin period b on the alternate blinded treatment with similar titration and assessment, initially weekly and then every other week for a total of another 8 weeks. the purpose of the study is to determine whether iloperidone is effective in the treatment of some symptoms in patients with ptsd, particularly difficulty falling or staying asleep, trauma dreams and daytime irritability or outbursts.

Eligibility criteria:
inclusion criteria: * ptsd diagnosis exclusion criteria: * pregnancy * traumatic brain injury greater than mild * primary sleep disorder * caffeinism * active substance use disorder * active suicidal risk * antipsychotic medication, antibiotics, sedatives, some antihypertensive or antiarrhythmic medication

Keywords: post traumatic stress disorder treatment of post traumatic stress disorder symptoms of arousal in post traumatic stress disorder iloperidone in post traumatic stress disorder
evaluate the efficacy and safety of activated t-lymphocyte cell therapy in advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: phase 2 clinical trial to evaluate the efficacy and safety of activated t-lymphocyte ("immuncell-lc") cell therapy in gemcitabine refractory advanced pancreatic cancer

this was designed as a single-center, single group clinical trial, and subjects include patients with pathologically-confirmed gemcitabine refractory advanced pancreatic cancer. if subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. to participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 2 weeks before administration. subjects should visit to hospital according to the protocol and receive a study drug. therapeutic response rate, overall survival rate, time to progression and the quality of life should be investigated.

Eligibility criteria:
inclusion criteria: 1. subject who signed the written consent form by themselves, protectors or legal representatives prior to the clinical trial after the person in charge explained fully about objectives, procedure and the characteristics of the study drug. 2. patient aged 18 to 75 3. patient with pathologically-confirmed, advanced pancreatic cancer 4. ecog scale (ecog-ps) ≤2 (appendix 4. performance status scale/score) 5. patient with anticipated survival period of more than 3 months 6. patient with progressed disease after gemcitabine-based primary anti-cancer chemotherapy 7. patient whose blood test, renal function test and liver function test results meet the following conditions. exclusion criteria: 1. patient with the medical history of immunodeficiency or autoimmune disease that could be aggravated by immunotherapy (examples: rheumatoid arthritis, systemic lupus erythematosus, vasculitis, multiple sclerosis, adolescent insulin-dependent diabetes mellitus, etc.) 2. confirmed immunodeficient patient 3. patient with the history of cancer other than skin cancer, local prostate cancer or carcinoma in situ of cervix within the last 5 years of the start of study 4. patient who has received systemic anti-angiogenic agent 5. patient who has received a chemotherapy other than gemcitabine based chemotherapy 6. obvious myocardial failure or uncontrolled arterial hypertension 7. patient who has experienced serious allergy (judged by the investigator) 8. patient with serious psychological disease (judged by the investigator) 9. pregnant woman, breast-feeding woman or woman who want to be pregnant during the trial period 10. patient who has participated in another clinical trial within the last 4 weeks of the start of study

Keywords: advanced pancreatic cancer